18 Mar 2014

Azarga (Brinzolamide / Timololo) - Italia

ATC: S01ED
SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
BETA BLOCKING AGENTS
Azarga

Last Updated on 18 Mar 2014 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Azarga Indication

Riduzione della pressione intraoculare (PIO) in pazienti adulti con glaucoma ad angolo aperto o ipertensione oculare per i quali la monoterapia produce una riduzione della PIO insufficiente.

Azarga Generic Name

Brinzolamide / Timololo

Type

POM

Summary Product Characteristics (SPCs) Links
Riassunto delle Caratteristiche del Prodotto - Azarga (external site)

Related Learning Zones

CLL Knowledge Centre and CME

CLL Knowledge Centre and CME

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within four main sections: ‘Disease Awareness’, ‘Events’, ‘Resources’, and 'CME'. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing,

The CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been EACCME-accredited and awarded 1 CME credit. Test your knowledge by answering quiz questions based on patient case study scenarios.

Hypogonadism Knowledge Centre

Hypogonadism Knowledge Centre

The Hypogonadism Knowledge Centre provides healthcare professionals with free access to disease awareness sections such as epidemiology, pathophysiology, signs and symptoms, treatment options to assist the process of diagnosis, treatment and monitoring of patients with the condition. The regularly updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

G.MKT.GM.MH.01.2016.0364

Related Information

Azarga Marketing Information

Azarga Generic Name
Brinzolamide / Timololo
Marketing Company
Alcon Laboratories (UK) Ltd.
Drug Type
POM
Date of Issue, Marketing Authority

25/11/2008

Related Drugs - Eye Health and Disorders

Back to top